-
Challenge Seeks Methods to More Accurately Detect Epilepsy
2 June 2014. Mayo Clinic in Rochester, Minnesota and University of Pennsylvania in Philadelphia are seeking through an open competition new techniques to detect epilepsy seizures sooner and more accurately. The Seizure Detection Challenge has a total prize purse of $8,000 and a deadline for submissions of 19 August 2014. Epilepsy is a neurological disorder…
-
Quest, Sloan Kettering Partner on Solid Tumor Diagnostics
2 June 2014. Quest Diagnostics in Madison, New Jersey and Memorial Sloan Kettering Cancer Center in New York are developing tests to give physicians more precise data on genetic causes of solid tumor cancers, such as breast, prostate, colon, and lung cancer. Financial and intellectual property aspects of the collaboration were not disclosed. In the…
-
Stress, Diet Apps Numerous but Offer Only Short Term Help
30 May 2014. Online and mobile apps for stress management and healthy eating are numerous and gaining more users, but their impact appears to be short lived, according to an analysis by a researcher in Finland. Kirsikka Kaipainen, a research scientist at VTT Technical Research Centre in Espoo, Finland, published her findings earlier this month…
-
Epigenetics Biotech Secures $12.9 Million Early Financing
30 May 2014. Rodin Therapeutics Inc., a biotechnology company in Boston developing therapies based on epigenetics — inherited changes in genetic activity outside of DNA — raised $12.9 million in its first venture funding round. The company is a joint venture of Proteros biostructures GmbH in Munich and Atlas Ventures in Cambridge, Massachusetts. Rodin Therapeutics…
-
More Efficient Growth Factor Delivery Technique Devised
29 May 2014. Biologists and engineers at Georgia Institute of Technology in Atlanta developed a new process that delivers tissue-building proteins used in regenerative medicine known as growth factors in much higher concentrations than current methods. The team led by Georgia Tech bioengineering professor Todd McDevitt published its findings online yesterday in the journal Biomaterials…
-
Remote Heart Failure Monitoring Device Approved by FDA
29 May 2014. The U.S. Food and Drug Administration yesterday approved an implanted device that measures pulmonary artery pressure and heart rate of patients with moderate heart failure who were hospitalized in the previous year. The device, the CardioMEMS HF System, is made by CardioMEMS Inc. in Atlanta. St. Jude Medical, a medical device manufacturer…
-
Ohio State, Cancer Center Partner on Research Database
28 May 2014. Moffitt Cancer Center in Tampa and Ohio State University’s Comprehensive Cancer Center in Columbus are launching a repository of patient data and tumor samples to speed development of therapies and better match patients to clinical trials. Financial details of the Oncology Research Information Exchange Network or Orien created by the collaboration were…
-
Medical Centers to Develop Brain Signal Tracking, Therapies
28 May 2014. Massachusetts General Hospital in Boston and University of California in San Francisco are developing technologies to analyze brain activity and deliver near real-time neural stimulation therapies. The five-year project is funded by grants from Defense Advanced Research Projects Agency (DARPA) of $30 million and $26 million respectively to Mass. General and UC-San…
-
Five Pharma Companies to Share Clinical Researcher Data
27 May 2014. Five pharmaceutical companies are joining together to share their files on researchers conducting clinical trials, to speed the administrative process of starting up new studies. The Investigator Databank is a joint project of Novartis, Janssen (a division of Johnson & Johnson), Merck, Eli Lilly and Co., and Pfizer, and administered by DrugDev,…
-
Drug Sensitivity Target Identified for Mesothelioma Therapy
27 May 2014. Researchers at the biopharmaceutical company Verastem Inc. in Cambridge, Massachusetts found the loss of a certain tumor suppressor improves responsiveness to therapies targeting cancer stem cells that treat mesothelioma, an aggressive form of lung cancer. The team led by Verastem’s research director Jonathan Pachter, with colleagues from Fox Chase Cancer Center in…